Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy

Bone Marrow Transplantation

Volumn 51, Issue 9, 2016, Pages 1241-1244

  Vasu, S ^a   Wu, H ^a   Satoskar, A ^a   Puto, M ^b   Roddy, J ^b   Blum, W ^a   Klisovic, R ^a   Andritsos, L ^a   Hofmeister, C ^a   Benson, D M ^a   Efebera, Y ^a   Jaglowski, S ^a   Penza, S ^a   Cohen, D ^a   Devine, S ^a   Cataland, S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CIPROFLOXACIN; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATININE; ECULIZUMAB; HAPTOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; MENINGOCOCCUS VACCINE; RAPAMYCIN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; BLOOD GROUP ABO INCOMPATIBILITY; BRONCHIOLITIS OBLITERANS; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLEMENT ALTERNATIVE PATHWAY; CREATININE BLOOD LEVEL; DEATH; DISEASE COURSE; DRUG INDICATION; DRUG WITHDRAWAL; ENDOTHELIUM INJURY; ENZYME ACTIVITY; ERYTHROCYTE DISORDER; FEMALE; GRAFT VERSUS HOST REACTION; HEART FUNCTION; HEMATOPOIETIC CELL TRANSPLANT THROMBOTIC MICROANGIOPATHY; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPOXIA; INFECTIOUS COMPLICATION; KIDNEY BIOPSY; KIDNEY INJURY; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LUNG BIOPSY; LUNG EMBOLISM; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PLASMA EXCHANGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RADIATION; RETROSPECTIVE STUDY; RISK FACTOR; SCHISTOCYTOSIS; THROMBOCYTE ACTIVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INFECTION; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; COMPLEMENT ACTIVATION; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT C5; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84963621743     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.87     Document Type: Letter

References (18)

1. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124: 645-653.
2. Chapin J, Shore T, Forsberg P, Desman G, Van Besien K, Laurence J. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol 2014; 12: 565-573.
3. Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009; 69: 183-198.
4. Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014; 123: 2478-2484.
5. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95-100.
6. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-575.
7. Negrini S, Durrbach A, Becquemont L. Sirolimus-related systemic thrombotic microangiopathy after renal transplantation. Therapie 2014; 69: 175-177.
8. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-557.
9. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709-719.
10. Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. New Engl J Med 2013; 369: 1379-1380.
11. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantationassociated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20: 518-525.
12. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014; 123: 3733-3738.
13. Labrador J, Lopez-Corral L, Lopez-Godino O, Vazquez L, Cabrero-Calvo M, Perez-Lopez R et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant 2014; 49: 684-690.
14. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 2014; 123: 2017-2025.
15. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29: 191-204.
16. Martinez MT, Bucher C, Stussi G, Heim D, Buser A, Tsakiris DA et al. Transplantassociated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2005; 36: 993-1000.
17. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-1726.
18. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged 4/= 10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64: 608-612.